COVID-19 in PID Survey

Worldwide COVID-19 in Children and Adult Patients With Primary ImmunoDeficiencies (PID) Survey

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04459689

Acronym

COPID19

Enrollment

200

Registered

2020-07-07

Start date

2020-03-15

Completion date

2027-02-18

Last updated

2026-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID, Primary Immune Deficiency

Brief summary

With the emergence of SARS-CoV-2 and the COVID-19 pandemic, there is an urgent need to understand the impact of infection on immunodeficient individuals. Whilst co-morbidities (such as diabetes, cancer, arterial hypertension, heart disease...) have been documented in people infected with SARS-CoV-2, there is currently no information on the consequences and outcomes for individuals with primary immunodeficiencies (PID). Following the 1st phase of the survey (launched by Isabelle Meyts (ESID), Nizar Mahlaoui (CEREDIH & IPOPI) and Kate Sullivan with Stuart Tangye (IUIS), that gave an idea of the number of affected PID patients and the impact of SARS-CoV-2 and directly focusing on obtaining this top level of information), we are launching the 2nd phase: "COPID19". COPID19 survey is a secured online GDPR compliant platform based in Paris (Imagine Institute). It has been approved by the Paris-Necker-Enfants malades IRB and Ethics Committee. However, this retrospective survey is designed for global distribution. Data can be entered by a health care professional (mostly clinicians) through a personal login and password. Each documenting person will have access to his/her own patients' data. COPID19 require a greater level of information than the 1st phase. The eCRF will be open to evolutions depending on progresses in our knowledge of this pandemic.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

0 Years to No maximum

Inclusion criteria

* Diagnosed with a Primary Immune Deficiency * COVID-19 (proven or probable)

Exclusion criteria

* Secondary Immune Deficiency * Other Coronovirus infection

Design outcomes

Primary

Measure	Time frame
Survival of patients with PID affected by COVID-19	Baseline
Rate of admission to ICU of patients with PID affected by COVID-19	Baseline
Rate of oxygen therapy of patients with PID affected by COVID-19	Baseline

Secondary

Measure	Time frame
Sequelae of patients with PID affected by COVID-19	Baseline

Countries

France

Contacts

CONTACTNizar MAHLAOUI, MD, MPH, PhD

nizar.mahlaoui@aphp.fr+33144494622

CONTACTHassan FAOUR, BS

supportdatabase@institutimagine.org+33 1 42 75 44 73

STUDY_CHAIRNizar MAHLAOUI, MD, MPH, PhD

Necker Enfants Malades University Hospital

Outcome results